Announcement • Apr 16
Tempest Therapeutics, Inc. Appoints Andrew Fang, Ph.D. as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts Tempest Therapeutics, Inc. announced the appointment of Andrew Fang, Ph.D. as Head of Business Development. Dr. Fang will lead Tempest’s global business development efforts, including strategic partnerships, cross-border licensing and corporate transactions, with a particular focus on expanding Tempest’s outreach and partnering efforts in China. The appointment reflects Tempest’s increasing emphasis on business development as a core strategic priority, including pursuing potential partnerships for its Phase 3-ready small molecule program, amezalpat, and advancing strategic collaborations across its CAR-T portfolio. Dr. Fang is a Founding Partner and Principal of YQ Advisors, where he focuses on strategic transactions and value creation in biotechnology and emerging technologies. He brings extensive experience across cross-border licensing, asset transactions, biotech financing and public-company strategic initiatives. At YQ Advisors, Dr. Fang has focused on ex-China/global licensing, M&A and reverse merger opportunities involving public biotechnology companies, as well as incubation of early-stage biotechnology platforms, particularly in cell and gene therapy and AI-enabled biotechnology. Dr. Fang has developed substantial experience in the cell and gene therapy space, with an emphasis on CAR-T, and brings strong connectivity to Chinese biotech clinical resources, strategic investors and potential operating partners, to support the evaluation, development and strategic positioning of innovative therapeutic programs in this area. Announcement • Apr 04
Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors On April 3, 2026, Tempest Therapeutics, Inc. closed the transaction and received proceeds of $1,999,539 from 3 investors pursuant to Regulation D. The company paid sales commission of $105,000. New Risk • Mar 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 3.3% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (299% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$34m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$24.1m market cap). 
